Articles
Search articles by year of publication.
Search articles by industry.
Industry
- Aerospace
- Agriculture
- Alcohol
- Apparel
- Automotive
- Biotechnology
- Crypto
- Digitalization
- E-commerce
- Education
- Education Technology
- Employee Ownership
- Energy
- Entertainment
- Entrepreneurship
- Fashion
- FinTech
- Finance
- Financial Services
- Food
- Gaming
- Government
- Grocery
- Healthcare
- Industrial
- Information Technology
- Infrastructure
- Interview
- Marijuana
- Media and Entertainment
- Metals and Mining
- Pharmaceuticals
- Power and Utilities
- Private Equity
- Product Strategy
- Products and Consumer Goods
- Professional Services
- Racing
- Real Estate
- Restaurant and Hospitality
- Retail
- Security
- Services
- Social Impact
- Social Media
- Software
- Space Exploration
- Sports
- Start-ups
- Sustainability
Pfizer: Pounds to Profits
To outpace competitors in the race to develop the first semaglutide weight-loss pill, Pfizer should partner with Kallyope.
Cost Plus Drugs: Prescription for Success
Cost Plus Drugs should acquire India based PharmEasy to grow internationally.
Seeing Green with Psychedelics
With the emergence of psychedelics as a treatment option for mental health-related illnesses, Big Pharma should partner with pureplay biotech firms to reap the benefits of these breakthrough therapies.
Teva: Don't Be so Generic
In the face of squeezed margins in the generics industry, Teva must diversify revenues into the nascent biosimilar space to remain profitable.
Gilead: Cultivating the Pipeline
In order to restore investor confidence and hedge legacy market downturns, Gilead needs to diversify into other channels of sustainable revenue generation to minimize volatility
Bioprinting a New Hope
Testing new drugs on 3D printed microtissues may be the solution to Roche’s R&D woes
The Perfect Remedy
Could drug incubation allow Canada to better compete in the global pharmaceutical industry?
The Battle Over Your Genes
The ACLU v. Myriad Genetics suit and the issues raised by gene patents
